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Abstract
Objective: To quantify the benefits and the survival rates between Thoracic Endovascular Aortic
Repair (TEVAR) and medical management for Acute Uncomplicated Type B Aortic Dissection
(TBAD).
Methods: The investigation was based on a literature review of evidence-based articles that were
relevant to the study. The articles were critiqued to compare the benefits of TEVAR and medical
management of TBAD on cardiovascular outcomes and survival rates in concerned stakeholders.
Results: The literature review reflected that TEVAR is more effective than the medical
management of TBAD when the condition was in the acute and uncomplicated stages.
Uncontrolled blood pressure remains an independent and significant risk factor for the disease.
The review further indicated that open surgery significantly increased the risk of hospitalized
mortality in TBAD patients. Conversely, medical management aimed to reduce blood pressure
showed an increase in complications such as malperfusion. Therefore, endovascular surgical
procedures such as TEVAR are gaining acceptance in the management of acute uncomplicated
TBAD.
Keywords: TBAD, TEVAR, aortic dissection, hypertension, treatment, and management
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Type B Aortic Dissection Definition and Clinical Significance
Type B aortic dissection (TBAD) is a clinical condition that affects the aorta distal to the
left subclavian artery (LSA) but does not affect the aortic arch and the ascending aorta. The aorta
is the largest artery in the body and can be described as a cane shaped blood vessel that
originates in the chest beginning at the top of the heart and extending into the abdomen. The
aorta, being an artery, carries oxygen-rich blood from the heart to the rest of the body.
Structurally, the aorta consists of three layers: the inner layer- tunica intima, the middle layertunica media, and the outer layer- tunica adventitia, all which provide strength to incur the large
amount of blood volume that is continuously pumping against the artery walls. However, in
some circumstances there is weakening of these layers creating a tear in at least one layer of the
aorta also known as an aortic dissection.
As previously mentioned, a tear typically occurs at a weak point in the artery-- in this
case through the layer of the tunica intima. If the tear is left untreated it will enlarge. This occurs
when blood passes through the tear between the inner and middle layer of the aortic wall,
causing the layers to separate from one another, or dissect. This new space is referred to as a
false lumen. Since blood is now entering the false lumen it is no longer flowing properly to the
rest of the body. Over time, the pooling of blood in between the tunica intima and tunica media
layers further weakens the aortic wall and, in some instances, can break through the tunica
adventitia layer causing a life-threatening loss of blood and drop in blood pressure. The lack of
blood flow to more distal portions of the body also negatively affects other important organs that
were previously perfused by the aorta and can lead to complications such as heart attack, kidney
failure, stroke and intestinal ischemia to list a few.
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Risk Factors for TBAD
TBAD is a detrimental condition of patients suffering from a variety of diseases
including, but not limited to smoking, Marfan syndrome, atherosclerotic cardiovascular disease
(ASCVD), aortic valve defects, certain systemic rheumatic diseases, syphilis and uncontrolled
blood pressure.1, 2 Hypertension (HTN) being the major independent and predisposing risk factor
for an aortic dissection. In 2017, new guidelines from the American Heart Association (AHA),
the American College of Cardiology (ACC); and nine other health organizations lowered the
numbers for the diagnosis of HTN to 130/80 millimeters of mercury (mm Hg) and higher for all
adults. The previous guidelines set the threshold at 140/90 mm Hg for people younger than age
65 and 150/80 mm Hg for those ages 65 and older.3 Managing uncontrolled hypertension is a
major priority for preventing the severity and risk of TBAD. High blood pressure predisposes an
individual to the risk of TBAD based on the simple pathophysiology-- blood pressure is the
product of minute volume and cardiac output. The risk of aortic dissection is increased if a larger
amount of blood enters circulation and the power of accommodation of the aorta is
compromised.
Low blood pressure is often considered an added advantage in patients with aortic
dissection. However, hypotension still puts the patient at risk of developing illnesses such as
ischemia and malperfusion; complications that are detrimental to overall health.4 Maintaining
blood pressure lower than the recommendations made by the above health organizations,
including ACC and the AHA, are optimal and crucial in urgent resolution of aortic dissections.
Classifications of TBAD
TBAD is classified into acute and chronic based on the onset of symptoms related to the
dissection. The disease is acute when the symptoms of dissection surface within two weeks and
4

symptoms occurring after thirty days are considered chronic.2 However, some guidelines suggest
a sub-acute phase occurs when symptoms surface beyond the first two weeks but within 30 days
of the aortic dissection. Studies suggest that 74% of the patients with acute TBAD exhibit
complications and mortality within the first two weeks.2,5
Apart from its classification based on the time of onset of symptoms, TBAD is also
classified into complicated and uncomplicated. Complicated TBADs are referred to as those
where the rate of hospitalized mortality is approximately 50% or greater. Uncomplicated TBADs
are if the rate of hospitalized mortality approximates 10% or less.2 Approximately 25-40% of
TBADs are considered complicated with at least one of the following characteristics: end organ
or lower extremity malperfusion, rupture, shock, neurologic compromise, refractory pain,
refractory hypertension, or early progression of disease.2
Traditionally TBADs have been managed therapeutically, by controlling pain and
providing anti-impulse therapy in the form of blood pressure lowering medications or open
surgery. Surgical mortality is reported to exceed more than 30% and considerable morbidity;
including spinal cord ischemia, cerebrovascular accident, and renal failure. However, new
research suggests a superior treatment option, minimally invasive Thoracic Endovascular Aortic
Repair (TEVAR).
TEVAR Technique and Procedure
Endovascular surgical procedures, such as TEVAR, are associated with improved clinical
outcomes in TBAD patients. The objective is not only meant to treat acute and complicated
TBAD, but also to reduce the adverse effects of hypertension.5 The TEVAR technique is
revolutionary in the field of cardiovascular surgery. Widely agreed upon is the improvement in
early outcomes seen with TEVAR for acute complicated TBAD. In non-randomized studies,
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morbidity and mortality were improved with early adoption of endovascular repair.6 First
introduced by Drake et al in 1994, the first commercial device which gained US Food and Drug
Administration approval for this indication in 2005.7,8
The goal of treatment is to redirect blood flow back to the true lumen by sealing the
proximal entry tear, hindering frank or impending aortic rupture and restoration of dynamic
malperfusion- this process is termed as aortic remodeling. During this process the false lumen is
gradually thrombosed and true lumen is enlarged but without enlargement of the total aortic
diameter.9 The factors that are considered when gauging the procedures viability are the lumen
diameter, which must be larger than 22 mm; the location of the affected area of the aorta, and the
areas that have suffered dissection. The treatment of TBAD is conducted at the lumen levelinvolving identification of the healthy aorta zone and the ability to gain entry through the
dissection. Appropriately sized sections of endograft are then placed on areas called landing
zones, or unaffected areas, alleviating blood pressure on the aorta, allowing blood to pass
through it without pushing on the weakened aortic wall.10 The endograft is then covered
depending on the aorta’s length as a measure to contain the aortic dissection within the specific
setting and avert its progression. In this setting, the descending aorta is aligned towards the
subclavian artery and any form of alteration can be detrimental to the patient’s health; then the
endovascular repair is conducted comprehensively.11 To minimize the retrograde perfusion that
stems from the subclavian artery, the graft has to enter through the false lumen. Using this
technique allows for better control of protrusions into the ostium of a branch vessel, known as
dynamic dissection, which is the most common cause of malperfusion syndrome. The
significance of this cautionary measure is to ensure that the proximal artery is covered from any
form of tearing. Using the endograft to create an expansion of the lumen is sufficient to fix the
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problem. If there is failure in achieving reperfusion, the most suitable solution is to expand the
lumen for inserting the stent through the bare stent technique. Furthermore, aortic remodeling
after TEVAR has been reported to be a significant prognostic factor for better outcomes.
There has been significant progress in treating aortic dissections with the use of
endovascular technology.13 The first successful TEVAR surgery was conducted using stent
grafting. TEVAR has been recorded as an impactful process in lowering the incidence of late
complications in patients who are prone to recurrence during remodelling.14 Moreover, patients
who are suffering from TBAD and undergo alternative treatment options, such as being managed
medically or with open surgery, could be subjected to other complications such as the
development of malperfusion syndrome and-future rupture events. TEVAR is a noteworthy
therapeutic option for the treatment and diagnosis of acute uncomplicated TBAD. Despite the
introduction and superiority of TEVAR assisting in elective repairs, its adoption is low across the
medical community.
Medical Therapy
Traditionally medical therapy, composed of pain medications, anti-impulse therapy (betablockers, vasodilators and short acting calcium channel blockers), and a goal systolic blood
pressure of (100-120 mm Hg and heart rate under 60 beats per minute), was the most viable
treatment option for treating aortic dissection.15-18 While medical therapy for acute complicated
TBADs remains relevant and should be initiated in all patients as soon as a diagnosis of
dissection is made, it should no longer be considered an appropriate solo therapy unless the
patient is unsuitable for TEVAR anatomically, or high risk for an open surgical approach. The
International Registry of Acute Aortic Dissection (IRAD) highlighted the mortality that occurs
after the administration of medical therapy itself leads to the development of refractory
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hypertension. TBAD patients must have strict blood pressure requirements and ensure that their
blood pressure remains within the optimal range. Moreover, a substantial difference was noted
when TEVAR therapy was applied over the use of medical therapy and/or open surgery in
treatment of TBAD, which supports evidence that TEVAR is highly effective and does not affect
patients who have refractory hypertension.10, 19 IRAD revealed that patients with refractory
hypertension were at a 20-fold risk of mortality from TBAD when they were managed with
medical therapy alone.1 Hence, thoracic endovascular repair (TEVAR) has emerged as a viable
option for managing TBAD. Unfortunately, patients of acute and uncomplicated TBAD are
typically forced to use pharmaceuticals as first-line treatment being that this is universally
considered the mainstay treatment; even though there is a better survival rate when medical
therapy is accompanied by TEVAR.14 The use of medication alone is not effective in the
treatment of TBAD as it presents an increased risk of mortality due to malperfusion and there is
a need to utilize TEVAR as early as possible. TEVAR boosts the restoration of open
perforations, especially to those at risk of complicated TBADs.20 In addition, the current
pharmaceutical therapy used to facilitate the repair of these perforations could be damaging to
the circulatory system causing inadequate cerebral, coronary, and renal perfusion.
Treatment of TBAD
Currently there is an ongoing debate regarding the most appropriate management of
TBADs due to the clinical complications that arise with both endovascular and pharmaceutical
therapy. The most important aspect of treating TBADs is identifying a sustainable, stable and
long-term treatment plan that not only prevents rupture but also controls further aneurysmal
degeneration. The treatment of TBAD is only conclusive if it involves aggressive management of
a patient’s uncontrolled blood pressure, and this is achieved through the use of pharmaceutical
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management.4 Several studies assert that medical treatment alone is not sufficient in eliminating
the adverse effects of TBADs as it may lead to considerable risks including disease progression
and aneurysmal degeneration, especially in those who are prone to developing hypertension, as
opposed to controlling the state.14,2 Also, when dealing with pharmaceutical management alone,
there is a likelihood of developing thrombosis with an estimated rate of 97%.21,13 This rate is
high in comparison to the adverse effects that occur when curative treatments are compared with
TEVAR, which indicates that the latter is more effective in the treatment of TBAD.
In comparison, it is clear that the TEVAR with pharmaceutical management is more
effective than medication alone in the treatment of acute and uncomplicated TBAD as it involves
the direct insertion of the regimen to the area affected by the aortic dissection.5 Also, the use of
TEVAR technique has been deemed successful as it does not interfere with the aortic dilation as
it is advanced through the false lumen leaving the true lumen untouched. Therefore, it does not
cause aortic rupture if the patient undergoes follow-up for at least a year after treatment. No
mortality has been observed after 30 days of intervention when dealing with either medical
management or TEVAR and the overall endpoint is typically found to be successful.10
In another study undertaken to gauge the most effective intervention between TEVAR
and medical treatment alone, the authors concluded that the former was appropriate due to the
prevention of developing thrombosis after the initial diagnosis.10 This infers that the
interventions are highly effective in the reduction of lumen diameter and the restoration of the
artery rupture as a result of acute and uncomplicated TBAD. The study also affirms that the use
of drugs for TBAD patients is a viable intervention for those who cannot afford a comprehensive
endovascular treatment at least two years after the initial diagnosis.1, 5 Therefore, TEVAR
presents an appropriate response for patients depending on the level of disease severity and the
9

type of medication being used to reduce blood pressure to ensure the stability of the condition.
Overall, TEVAR is seen as a lower risk procedure in the treatment of acute and uncomplicated
TBAD and it has short-term adverse effects and long-term survival rates of at least 70%, but
there is a need for follow up for at least a year.11 There is a level of agreement that
pharmaceutical management is the first line intervention in the treatment of TBAD, but it is only
successful in the presence of surveillance imaging and when the condition is short-term and
uncomplicated.
Quality of Evidence and Affect in Clinical Practice
Following the analysis of research on TBAD, a life-threatening condition that alters the
cardiac system, various interventions have been evaluated to gauge the most suitable and costeffective option to patients. The understanding of all available medical interventions will help
health practitioners and patients decide on the most appropriate treatment plan for a patient
depending on the severity of TBAD. According to the systemic reviews of articles on TBAD and
its treatment, it is clear that using TEVAR as the intervention is more appropriate as it has fewer
adverse effects, and it has long-lasting positive results. TEVAR is highly effective as it does not
alter the functions of the aorta.
The choice of medication alone is successful if the patient’s need in containing the acute
and uncomplicated TBAD is short-term, and if it is detected early. Medical treatment alone has
adverse effects, including rebound high blood pressure, which can be fatal for TBAD patients.
Therefore, as much as medical therapy is beneficial to the treatment of short-term and
uncomplicated TBAD, it is not sustainable for patients who have a chronic disease progression
and the health risks are likely to elevate over five years.
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